{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:18:28Z","timestamp":1793369908174,"version":"4.5.0"},"reference-count":40,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHas) is a standard of care for premenopausal patients with high-risk stage II\/III hormone receptor\u2013positive breast cancer (BC). Practical guidance on the optimal choice of GnRHa, timing, schedule, and monitoring is limited. Our aim was to determine how oncologists use OFS in routine care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>We designed a questionnaire to determine the choice of GnRHa, schedule, duration, initiation, use of bone modifiers, and monitoring of estradiol (E2). The questionnaire was sent to oncologists treating BC, in practice for &gt;1 year and participating in the ASCO Research Survey Pool (RSP). It was also forwarded by investigators to oncologists meeting these criteria. The survey was open between November 14, 2023, and January 5, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 996 oncologists participating in the ASCO RSP, 178 (18%) completed the survey. An additional 56 oncologists contacted by investigators responded. Respondents were from the United States (57%), Asia (15%), and Europe (14%). Goserelin (54%) and leuprolide (39%) were the most frequently used GnRHas and were administered once every month by 46%. Approaches to starting GnRHas were varied. Most continued them for the duration of aromatase inhibitor therapy (57%). Estradiol monitoring was performed regularly, sometimes, or never by 43%, 27%, and 27%, respectively. The E2 assays used were standard (65%), ultrasensitive (16%), and unknown (14%). Interpreting E2 assay results were considered difficult by 55%; however, 62% of oncologists changed treatment on the basis of them. A total of 92% of respondents would like ASCO guidance on the practical use of OFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Considerable practice variation exists for similar clinical scenarios in OFS administration. Respondents would welcome ASCO guidance on all aspects of OFS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/op-24-00502","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T15:59:11Z","timestamp":1731427151000},"page":"654-662","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":19,"title":["Clinical Management of Ovarian Function Suppression in Premenopausal Women With Breast Cancer: A Survey of Members of ASCO"],"prefix":"10.1200","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-6714","authenticated-orcid":true,"given":"Catherine M.","family":"Kelly","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Mater Private Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-7665","authenticated-orcid":true,"given":"Kathleen E.","family":"Bennett","sequence":"additional","affiliation":[{"name":"School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona","family":"Cahir","sequence":"additional","affiliation":[{"name":"School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Eisen","sequence":"additional","affiliation":[{"name":"Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, Canada"},{"name":"Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9632-6686","authenticated-orcid":true,"given":"Lajos","family":"Pusztai","sequence":"additional","affiliation":[{"name":"Center for Breast Cancer, Smilow Cancer Hospital, Yale, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(20)30215-1"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61074-1"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3694"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3493"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2022.09.007"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00777"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2013.08.009"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404037"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3171"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx285"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01967"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01064"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.503"},{"key":"e_1_3_5_15_2","first-page":"Cd013538","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui KT","year":"2020","unstructured":"Bui KT, Willson ML, Goel S, et al: Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer. Cochrane Database Syst Rev 3:Cd013538, 2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9573"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.007"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-016-0691-6"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-015-0593-z"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.665426"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-024-07323-9"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-010-1332-y"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.04.005"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-012-0354-1"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13722"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.6574"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.2259"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.524"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3780"},{"key":"e_1_3_5_30_2","unstructured":"National Comprehensive Cancer Network: Breast cancer. Version1.2024-January 25 2024 2024. http:\/\/NCCN.org"},{"key":"e_1_3_5_31_2","first-page":"130","article-title":"Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women","volume":"77","author":"Filicori M","year":"1993","unstructured":"Filicori M, Flamigni C, Cognigni G, et al: Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 77:130-133, 1993","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14168"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2019.60.4.244"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00296"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-015-0637-4"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050924"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00557"},{"key":"e_1_3_5_38_2","volume-title":"Decapeptyl (triptorelin) SR Summary of Product Characteristics","author":"medicines.ie","year":"2024","unstructured":"medicines.ie: Decapeptyl (triptorelin) SR Summary of Product Characteristics, 2024"},{"key":"e_1_3_5_39_2","volume-title":"Prostap SR DCS (leuprorelin acetate) Summary of Product Characteristics","author":"Medicines.ie","year":"2024","unstructured":"Medicines.ie: Prostap SR DCS (leuprorelin acetate) Summary of Product Characteristics. 2024"},{"key":"e_1_3_5_40_2","volume-title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive\/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) (NCT05879926)","year":"2024","unstructured":"ClinicalTrials.gov: Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive\/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) (NCT05879926). Bethesda, MD, National Library of Medicine (US), 2024"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2905"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-24-00502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:59:25Z","timestamp":1747159165000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-24-00502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1200\/OP-24-00502"],"URL":"https:\/\/doi.org\/10.1200\/op-24-00502","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"2024-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}